Report Preview

The global glycine-pharma grade market size was valued at USD 650 million in 2021 and is projected to reach around USD 1,000 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The growing consumption of meat and surging usage of products made with animal such as wool, leather, horn, and others, rising government initiatives to grow the population and increase the breeding activities of cattle are driving the glycine-pharma grade are expected to increase the market growth. On the other hand, several side effects related with the use and consumption of glycine such as nausea, vomiting, drowsiness, stomach upset, and diarrhea is one of the restraining factors limiting the growth.

In the pharmaceuticals industry, glycine is used as a section of amino acid mixtures for oral and parenteral use. It is used as a re-absorbable amino acid for cure of diarrhea and animal scours. Glycine is a useful transitional used in chemical synthesis of pharmacologically-active compounds. It has antimicrobial additive properties and has been shown to steady vitamin C. Definite pharmaceutical-grade products comprise glycine to recover gastric absorption of the drug. Further uses include sweetener, emulsifier, emollient, stabilizer, solubilizing agent, and buffer substance in various applications. Hence, rising pharmaceutical industry is estimated to boost the demand for glycine-pharma grade.

Due to the rising consumption of meat and increasing usage of products made using animal such as wool, horn, leather, and others, an important rise in population of cattle such as sheep, buffalo, goat, and others is being seen across the globe. For instance, according to the study by the Department of Animal Husbandry and Dairying, the population of sheep, goats, and cows reached 74.26 Mn, 148.88 Mn, and 145.91 Mn were recorded across India respectively in 2019. As glycine is used as a nutritional supplement in the animal feed sector, due to its capability to regulate all metabolic processes, rising population of cattle is anticipated to bolster the sales in the global market.

The COVID-19 outbreak increased on global economic disorder as it modelled some crippling challenges on various industries across the globe. The variable degrees of the nationwide lockdowns put to effect by numerous governments led to disturbing interferences in supply chains, alongside bringing trade barriers. However, the pandemic demonstrated to be beneficial for the demand and manufacture of glycine on account of its greater adoption in the pharma sector to assist in the cure of the COVID-19 virus and its other consequences. Numerous research activities are creating large use of glycine to alleviate the related tissue damages and the cytokine storm caused due to the infection.

Product Insights

The biosynthesis segment is anticipated to hold a greater market share and is expected to continue to grow at a steady rate throughout the forecast period. The factors for the growth of the segment is that biosynthesis is among the most common methods for manufacturing pharmaceutical-grade glycine. Additionally, the biopharmaceutical industry’s fast growth is favourably influencing the growth of this market sector. The use of chloroacetic acid amide solution preparation is receiving a lot of grip, and this market segment is anticipated to increase rapidly in the coming years.

End User Insights

In terms of end user, the glycine-pharma grade market is segmented into hospitals and labs. The hospitals segment is estimated to hold the maximum share in the evaluation timeframe. The rising prevalence in the number of patients suffering from kidney problems and excess growth in the renal population are boosting the growth of this segment.

Region Insights

North America dominates the glycine-pharma grade market, due to rising adoption of sedentary lifestyles and shifting eating habits, there is a sudden rise in metabolic syndrome and sleep problems, resulting in fuelling the demand for associated treatment and medications.

For instance, as per the American Sleep Association, nearly 50 to 70 million people in the U.S. have sleep disorders, among which 25 Mn of the adults suffers from obstructive sleep apnea. As glycine is widely used in the preparation of medication for the above-mentioned diseases, rising burden of sleep problems is anticipated to accelerate the demand in the global market.

However, Asia Pacific is expected to register growth at a rapid CAGR in the global market during the forecast period. Glycine is attaining higher popularity across the pharmaceutical industry due to its antimicrobial properties. It is comprehensively being employed in the treatment of numerous mental disorders, such as schizophrenia. Moreover, rising use of glycine as extra therapeutics for protecting kidneys from side effects, caused post the consumption of specific drugs after the organ transplantation is favouring the sales. So, increasing number of organ transplantation procedures across the nations such as Japan, South Korea, China, and others is anticipated to augment the growth in the Asia Pacific market.

Key Companies Insights

To stay competitive in the total market, players are using new approaches such as new product development, mergers and acquisitions, joint ventures, and geographic expansions. Some of the key players working in the global glycine-pharma grade market include:

• Ajinomoto
• GEO Specialty Chemicals
• Yuki Gosei Kogyo
• Guangrong Chemical
• Showa Denko KK
• Chattem Chemicals
• Evonik
• Paras Intermediates Private Limited
• Linxi Hongtai
• Shijiazhuang Donghua Jinlong Chemical
• Zhenxing Chemical
• Hebei Donghua Jiheng Chemical
• Hubei Xingfa Chemicals Group
• Other players

Some of the Recent Developments:

• In September 2020, Evonik Industries launched the guanidino acetic acid product, GuanAMINO, to fulfil the rising demand for enhanced energy metabolism in livestock production. The novelty is resulting from amino acids glycine and arginine.
• In 2017, Ajinomoto Health & Nutrition North America, Inc. acquired Cambrooke Therapeutics, Inc., a U.S.-based medical foods enterprise that produces amino acid products.

Segments

By Product

• Chloroacetic Acid Amide Solution
• Biosynthesis

By Application

• Antacid
• Therapeutic Agent for Muscular Dystrophy
• Antidote
• Others

By End Users

• Hospitals
• Labs

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt